Oral triptans are considered the industry gold standard acute treatments and there are currently seven approved, all with ...

At AAN 2025, three posters presented the sustained long-term efficacy and real-world impact of Lundbeck’s Vyepti for migraine ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

The HER-MES trial found that Aimovig (erenumab) was more effective at preventing migraine attacks and also better tolerated than topiramate, a generic epilepsy drug which is known to have side ...

The oral Nurtec (rimegepant) and Qulipta (atogepant) drugs are also considered first-line preventive ... Aimovig and Emgality are taken once a month as one or two successive shots, depending on the ...

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

A new report published in Brain Medicine reveals that a single dose of the drug Osanetant, administered shortly after a ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

While FDA drug and device reviewers and inspectors were protected from layoffs, drug reviews are likely to be affected, ...